R2 김형오 / Pf. 김시영.  Recent results  Presence of extensive lymphocytic infiltration in early stage breast cancer  Good prognosis  High response rates.

Slides:



Advertisements
Similar presentations
San Antonio Breast Cancer Symposia Authors: Dr. Sunil Verma Date posted: January 6 th, 2008.
Advertisements

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
Integration of Taxanes in the Management of Breast Cancer
Neo-adjuvant Chemotherapy for Breast Cancer
Xeloda X-panding options in the adjuvant treatment of breast cancer
516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.
Triple-Negative Breast Cancer
Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the.
Memorial Sloan-Kettering Cancer Center
Neoadjuvant Chemotherapy for Ca Breast CY Choi UCH.
Drug Treatment of Metastatic Breast Cancer
These slides were released by the speaker for internal use by Novartis.
SYB Case 2 By: Amy. History 63 y/o female History of left breast infiltrating duct carcinoma s/p mastectomy in 1996 and chemotherapy ER negative, PR negative,
Breast Carcinoma. Anatomy Epidemiology: 10% 17.1/10 28/10 46/ m world wide 6% develop cancer of the breast in their lifetime. 50,000 to 70,000.
First month Second Month First month Second Month Milk line remnant Milk line remnant Accessory axillary breast tissue Accessory axillary breast tissue.
1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.
Are there benefits from chemotherapy to early endometrial cancer
Should clinicians routinely recommend trastuzumab (Herceptin) as part of the adjuvant therapy for all patients with Her2 positive early breast cancer?
Breast Cancer Risk with Menopausal Hormone Use Jackie Bouillon Advisor: Dr. Robert Hadley Spring 2007.
Dubsky P et al. Proc SABCS 2012;Abstract S4-3.
TREATMENT Mastectomy -traditionally, treatment of breast ca has been surgical -19 century, surgical treatment : local excision ~ total mastectomy : radical.
Istituto Nazionale per la Ricerca sul Cancro Genoa – Italy
Effect of 21-Gene Reverse- Transcriptase Polymerase Chain Reaction Assay on Treatment Recommendations in Patients with Lymph Node-Positive and Estrogen.
Adjuvant chemotherapy – When should surgeons recommend? Joint Hospital Surgical Grand Round Dr Lorraine Chow Ruttonjee Hospital.
Taxanes — Taxanes are among the most active agents for metastatic breast cancer – Docetaxel, Paclitaxel, NabPaclitaxel. Anthracyclines – Doxorubicin, Epirubicin,
San Antonio Breast Cancer Symposium, December 8-12, 2015
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.
Response-Guided Neoadjuvant Chemotherapy for Breast Cancer Gunter von Minckwitz, Jens Uwe Blohmer, Serban Dan Costa, Carsten Denkert, Holger Eidtmann Journal.
Annals of Oncology 24: 2206–2223, 2013 R3 조영학
PHASE II RANDOMIZED STUDY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 – POSITIVE.
Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis.
Patterns of care and comparative effectiveness of endocrine therapy for premenopausal women with early breast cancer A multi-institution cohort study February.
Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,
CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.
CCO Independent Conference Coverage
Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone inpatients with advanced non-small cell lung cancer and a performance status.
Randomized Phase III Study Of Gemcitabine
Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.
Phase III PlanB Final Analysis: Adjuvant TC vs ECT in Pts With High-Risk HER2-Negative Early Breast Cancer CCO Independent Conference Highlights* of the.
Challenges for the treatment of breast cancer
Summary Author: Dr. C. Tom Kouroukis, MD MSc FRCPC
Università di Napoli Federico II
Slamon D et al. SABCS 2009;Abstract 62.
Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.
Comparison between Pathologic Characteristics of Her2 Negative and Positive Breast Cancer in a Single Cancer Center in Jordan DR Majdi A. Al Soudi, MD,
Update in Treatment of Early Breast Cancer
Breast Cancer Protocol
Prognostic significance of tumor subtypes in male breast cancer:
Dr Amit Gupta Associate Professor Dept Of Surgery
Perez EA et al. SABCS 2009;Abstract 80.
Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer.
CREATE-X: Adjuvant Capecitabine in HER2-Negative Breast Cancer
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
ASCO 2002 Advances in the Adjuvant Chemotherapy of Breast Cancer
THBT neoadjuvant endocrine therapy is to be used in post-menopausal breast cancer woman Antonino Grassadonia Università «G. D’Annunzio» – Chieti-Pescara.
Marcelo Calil Instituto Brasileiro de Controle do Câncer
Table (1):Relation between lymph node and molecular subtypes.
Swain SM et al. Proc SABCS 2012;Abstract P
OPTIMIZING NEOADJUVANT/ADJUVANT TREATMENT OPTIONS IN PATIENTS WITH BREAST CANCER DR LASEBIKAN NWAMAKA RADIATION AND CLINICAL ONCOLOGIST UNTH.
Thanh Nhan Hospital MALE BREAST CANCER: CASE REPORT
Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results.
徐慧萍1 羅竹君1,2 郭耀隆1 李國鼎1 國立成功大學醫學院附設醫院外科部1 國立成功大學醫學院臨床醫學研究所2
Untch M et al. Proc SABCS 2010;Abstract P
Effect of Obesity on Prognosis after Early Breast Cancer
Handling and Evaluation of Breast Cancer Biopsy
LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.
Volume 373, Issue 9676, Pages (May 2009)
Badwe RA et al. SABCS 2009;Abstract 72.
Published online Feb 7, 2019 Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling:
Presentation transcript:

R2 김형오 / Pf. 김시영

 Recent results  Presence of extensive lymphocytic infiltration in early stage breast cancer  Good prognosis  High response rates to neoadjuvant chemotherapy  TIL(Tumor-infiltrating lymphocytes)  Shown to be a good prognostic indicator ▪ Only in highly proliferative breast tumor ▪ Not routine

 Recent concept  Cell death induced by chemotherapies can promote permanant antitumor immunity ▪ Anthracyclines, oxaliplatin, gemcitabine etc ▪ May be critical for long-lasting remission  BIG(Breast International Group) study  Extensive follow up  Randomized  Prospectively planned

 To examine the hypothesis  Increased lymphocytic infiltration would be associated with good prognosis  Benefit from immunogenic chemotherapy in selected breast cancer subtypes

 BIG  Multicenter, randomized, prospective, phase III  2887 patients, LN (+), 1998~2001 ▪ A1 : Sequential control ▪ CMF 3 cycle -> doxorubicin 75mg/m2, 4 cycles ▪ A2 : Concurrent control ▪ CMF 3 cycle -> Doxorubicin 60mg/m2 4 cycles + cyclophosphamide 600mg/m2 ▪ B : Sequential docetaxel ▪ CMF 3 cycle -> docetaxel 100mg/m2 -> doxorubicin 75mg/m2 ▪ C : Concurrent doxetaxel ▪ CMF 3 cycle -> docetaxel 75mg/m2 + doxorubicin 50mg/m2 -> 2009 samples analyzed(69.6%)

 Definitions  Intratumoral lymphocytic infiltration ▪ Percentage of mononuclear cells within the epithelium of the invasive tumor cell nests  Stromal lymphocytic infiltration ▪ Percentage of tumor stroma containing infiltrating lymphocytes  Disease free survival(DFS) ▪ Date of random assignment ~ 1 st relapse, 2 nd primary, death  Overall survival(OS) ▪ Date of random assignment ~ date of death with any cause  Lymphocyte predominant breast cancer ▪ >=50% infiltration of stromal or intratumoral lymphocytic infiltration

 Group subtypes  ER, HER2 ▪ ER negative / HER2 negative ▪ HER2 overexpressing ▪ ER positive / HER 2 negative

 TILs and pathologics association  TILs(stromal/intratumoral) were associated with ▪ Infiltrating ductal histology, (P<0.001, p=0.048) ▪ High histologic grade, (p<0.001, p<0.001) ▪ Hormone receptor negativity, (P<0.001, p<0.001) ▪ Not associated with age, menopausal state, increasing lymph node involvement, tumor size  Median percentage ▪ Infiltration of intratumoral lymphocytes : 2% ▪ Stromal lymphocytes : 10%

10% increment of infiltration stromal, 15% reduction of risk for recurrence or death (17% risk of death) intratumoral 17% reduction of risk for recurrence or death (27% risk of death)

HER2(+), anthracycline only HER2(+), anthracycline, docetaxel

 Increasing lymphocytic infiltration of the tumor and stroma  Associated with good prognosis  Only in ER(-)/HER2(-) subgroup  Interaction between increasing stromal infiltration and chemotherapy regimen was seen only in the HER2(+)  Strengths  Size,  Randomization,  Long-term follow-up,  Two independent pathologic assessment  Increasing lymphocytic infiltration is a strong prognostic factor for the ER(-)/HER2(-) BC subtype